Tracy Leong Australia

Dr Leong is the Director of Interventional Pulmonology at Austin Health in Melbourne and Respiratory Clinical Lead in Lung Cancer. She is a senior Clinician Scientist at the Olivia Newton-John Cancer Research Institute, and is a founder of the TRACKER lung cancer biobank. She is the Chair of the Lung Cancer Working Party for the Thoracic Society of Australia and New Zealand and Chair of the Multidisciplinary Clinical Science Committee for the International Association for the Study of Lung Cancer.
Job Title
Director of Interventional Pulmonology
Faculty / Department / Division
Respiratory Medicine
Institution / Organisation
Austin Health

21 November 2026, Saturday

Time Session
09:30
10:30
Noni Novisari Soeroso Chairperson Indonesia
Tracy Leong Chairperson Australia
  • Kwun Fong Speaker Australia
    Omics (Genomics, Proteomics, and Multi-Omics) “omics” refers to the large-scale study of biological molecules in a tumor, including its DNA (genomics), RNA (transcriptomics), and proteins (proteomics). Omics can be considered essential in lung cancer for several reasons: • Precision Medicine and Targeted Therapy. Lung cancer is driven by diverse genetic mutations. Genomic profiling allows doctors to identify specific driver mutations (such as EGFR, ALK, ROS1, or BRAF) and match patients to targeted drugs as their effectiveness is dependent on the present of mutations. • Biomarker Discovery. Integrating multiple layers of omics data (multi-omics) can discover new biomarkers that predict how the behaviour of a lung cancer. • Overcoming Drug Resistance. Lung cancers can adapt and becomes resistant to treatment. Omics technologies can reveal how cancer cells adapt and change, thus revealing potential new actionable pathways.
  • Yoshinori Hasegawa Speaker Japan
    Cancer research possesses a long and rich history. Early landmark studies demonstrated chemical carcinogenesis induced by coal tar, establishing the foundational principle that external stimuli and chronic inflammation serve as crucial drivers of malignant transformation. Concurrently, extensive molecular investigations have elucidated that cancer development is a dynamic, multistep process governed by the sequential accumulation of somatic genetic mutations. Understanding how environmental triggers interact with intrinsic genomic landscapes remains largely unknown in modern oncology. In this symposium, we discuss the roles of host genetic susceptibility alongside environmental carcinogens—particularly ambient air pollution—in driving carcinogenesis, using epidermal growth factor receptor (EGFR) gene mutations as a prime biological model. Although numerous epidemiological studies have well documented a significantly higher prevalence of EGFR-mutant lung cancers among Asian populations, this distribution cannot be attributed to a single etiology. Instead, it is increasingly evident that a complex interplay of multiple genetic and environmental determinants underlies this phenomenon. To conceptualize these intricate interactions, we propose the "Host–Pollution–Driven Tumour Promotion" hypothesis as a working model. In this framework, germline host factors and exogenous exposures converge on altered immune surveillance and macrophage-driven inflammation to create a tumour-promoting context (Sunaga et al., Respirology,2026). By integrating host genomic predispositions with extrinsic environmental factors, this model provides a comprehensive mechanistic perspective on how non-mutagenic environmental pollutants can synergize with pre-existing genetic risks to facilitate tumor initiation and progression. Ultimately, exploring this paradigm deepens our understanding of multi-factorial carcinogenesis and highlights potential avenues for targeted prevention and early therapeutic intervention.
  • Henry Marshall Speaker Australia
  • Q&A
Ballroom 3, Lower Ground Floor
11:00
12:30

22 November 2026, Sunday

Time Session
11:00
12:00
Chong Kin Liam Chairperson Malaysia
Tan Sin Nee Chairperson Malaysia
  • Ildikó Horváth Speaker Hungary
  • Noni Novisari Soeroso Speaker Indonesia
    Lung Cancer Screening: Hurdles in Asia-Pacific Region Noni Novisari Soeroso Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Sumatera Utara, Medan, Indonesia Abstract Lung cancer is the leading cause of cancer-related death worldwide, and Asia carries a disproportionate share of the burden: over 60% of new cases and deaths occur there, and the Western Pacific Region alone accounts for nearly half of global cases. Although low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality, only 22% of countries in the Western Pacific have implemented screening programs. This review summarizes the main barriers to implementation across the Asia-Pacific region. First, high costs and limited reimbursement, especially in low- and middle-income countries. Second, inadequate infrastructure, including too few CT scanners and shortages of trained radiologists and thoracic specialists. Third, low public awareness and cultural barriers such as fear, stigma, and fatalism. A distinctive regional challenge is the high proportion of lung cancer in never-smokers, particularly Asian women, which makes Western smoking-based screening guidelines a poor fit. In addition, endemic tuberculosis increases false-positive LDCT findings, and no validated risk-prediction models exist for non-smoking Asian populations. Healthcare financing disparities, fragmented cancer registries, and vulnerability to climate-related disruptions further complicate implementation in low-resource settings. Addressing these barriers will require regionally adapted screening criteria that include non-smoking risk factors, investment in infrastructure and workforce training, integration of screening with tuberculosis and smoking-cessation programs, and sustained policy advocacy to secure government funding. Overcoming them is essential to reducing the large and growing burden of lung cancer across Asia-Pacific. Keywords: Lung cancer screening - Asia-Pacific - low-dose computed tomography - health equity - never-smokers - implementation barriers
  • Tracy Leong Speaker Australia
  • Q&A
Ballroom 3, Lower Ground Floor